Clinical Research Directory
Browse clinical research sites, groups, and studies.
Stemchymal® for Polyglutamine Spinocerebellar Ataxia
Sponsor: Steminent US, Inc.
Summary
The purpose of the clinical trial is to study the therapeutic efficacy and safety of Stemchymal® infusions for polyglutamine spinocerebellar ataxia treatment by a randomized, double-blind, placebo-controlled study design. Eligible subjects will receive Stemchymal® through intravenous infusion.
Official title: A Phase II, Randomized, Double-Blind, Placebo-controlled, Single-Center Study to Evaluate the Safety and Efficacy of Stemchymal (Allogeneic Adipose-derived Mesenchymal Stem Cells) Infusion for the Treatment of PolyQ Spinocerebellar Ataxia
Key Details
Gender
All
Age Range
20 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
20
Start Date
2025-06-01
Completion Date
2028-06-01
Last Updated
2024-05-02
Healthy Volunteers
No
Conditions
Interventions
Stemchymal
Patients will receive Stemchymal® through intravenous infusion
Placebo
Patients will receive Placebo through intravenous infusion